Redmile Group’s Akero Therapeutics AKRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-747,818
| Closed | -$35.5M | – | 35 |
|
|
2025
Q3 | $35.5M | Sell |
747,818
-26,493
| -3% | -$1.28M | 3.45% | 9 |
|
|
2025
Q2 | $41.3M | Sell |
774,311
-164,966
| -18% | -$7.5M | 4.4% | 10 |
|
|
2025
Q1 | $38M | Sell |
939,277
-295,932
| -24% | -$12.5M | 3.59% | 8 |
|
|
2024
Q4 | $34.4M | Sell |
1,235,209
-152,270
| -11% | -$4.61M | 2.39% | 14 |
|
|
2024
Q3 | $39.8M | Sell |
1,387,479
-226,994
| -14% | -$5.92M | 2.35% | 18 |
|
|
2024
Q2 | $37.9M | Sell |
1,614,473
-244,229
| -13% | -$5.22M | 2.29% | 17 |
|
|
2024
Q1 | $47M | Buy |
1,858,702
+749,226
| +68% | +$18M | 1.72% | 20 |
|
|
2023
Q4 | $25.9M | Sell |
1,109,476
-660,208
| -37% | -$13M | 0.93% | 31 |
|
|
2023
Q3 | $89.5M | Sell |
1,769,684
-41,988
| -2% | -$1.96M | 4.26% | 4 |
|
|
2023
Q2 | $84.6M | Sell |
1,811,672
-232,717
| -11% | -$10.7M | 3.25% | 5 |
|
|
2023
Q1 | $78.2M | Sell |
2,044,389
-588,523
| -22% | -$26.2M | 3.39% | 5 |
|
|
2022
Q4 | $144M | Buy |
2,632,912
+1,041,827
| +65% | +$44.6M | 5.9% | 3 |
|
|
2022
Q3 | $54.2M | Buy |
1,591,085
+3,800
| +0.2% | +$58.1K | 2.1% | 16 |
|
|
2022
Q2 | $15M | Sell |
1,587,285
-15,000
| -0.9% | -$156K | 0.57% | 42 |
|
|
2022
Q1 | $22.7M | Hold |
1,602,285
| – | – | 0.71% | 39 |
|
|
2021
Q4 | $33.9M | Sell |
1,602,285
-1,085,159
| -40% | -$24.1M | 0.77% | 36 |
|
|
2021
Q3 | $60.1M | Sell |
2,687,444
-117,500
| -4% | -$2.66M | 1.05% | 33 |
|
|
2021
Q2 | $69.6M | Buy |
2,804,944
+291,198
| +12% | +$8.18M | 1.03% | 32 |
|
|
2021
Q1 | $72.9M | Buy |
2,513,746
+191,189
| +8% | +$5.79M | 1.03% | 35 |
|
|
2020
Q4 | $59.9M | Sell |
2,322,557
-13,800
| -0.6% | -$384K | 0.73% | 41 |
|
|
2020
Q3 | $71.9M | Buy |
2,336,357
+1,944,205
| +496% | +$67.9M | 1.32% | 26 |
|
|
2020
Q2 | $9.77M | Sell |
392,152
-177,361
| -31% | -$4.05M | 0.18% | 67 |
|
|
2020
Q1 | $12.1M | Sell |
569,513
-594,489
| -51% | -$12.8M | 0.34% | 51 |
|
|
2019
Q4 | $25.8M | Sell |
1,164,002
-400
| -0% | -$8.28K | 0.62% | 42 |
|
|
2019
Q3 | $26.5M | Sell |
1,164,402
-4,400
| -0.4% | -$102K | 0.89% | 36 |
|
|
2019
Q2 | $22.4M | Buy |
+1,168,802
| New | +$22.2M | 0.63% | 48 |
|
Other funds holding AKRO
Redmile Group's AKRO Position: Q4 2025 in Review
Redmile Group sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 747,818 shares — an estimated $35.5M sold.
Redmile Group first reported a position in AKRO in Q2 2019 and held it in 26 quarters. The position peaked at $144M in Q4 2022. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.
- Redmile Group reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
- Redmile Group sold 747,818 Akero Therapeutics shares in Q4 2025, an estimated $35.5M.
- Redmile Group first reported a position in Akero Therapeutics in Q2 2019 and held it in 26 quarters.
- Redmile Group's Akero Therapeutics position peaked at $144M in Q4 2022.
- 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.
Based on Redmile Group's 13F filing for Q4 2025, filed 17 Feb 2026.